CMA closes probe into three Concordia drugs

The UK’s competition enforcer has shuttered part of its antitrust probe of drugmaker Concordia after deciding it did not have the need or resources to continue investigating three of the company’s drugs.

Unlock unlimited access to all Global Competition Review content